Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6420339B1 · kind B1 · utility
160Cited by
47References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 1998 |
| Grant date | Jul 16, 2002 |
| Priority date | — |
| Expiry date | Oct 14, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the chemical modification of biologically active agents. More, specifically, the invention relates to a novel approach to engineer, through mutagenesis and site-directed chemical conjugation, specific, well-defined dualPEGylated-protein bioconjugates, consisting of two polyethylene glycol (PEG) macromolecules chemically conjugated to the protein at two specifically defined amino acid residues. The described dualPEGylated-protein bioconjugates show substantially improved bioefficacy and biocompatibility.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.